Nintedanib

Nintedanib is a prescription-only medication used to treat adults with certain chronic, progressive lung diseases. These include idiopathic pulmonary fibrosis (IPF) and other fibrosing interstitial lung diseases. It belongs to the tyrosine kinase inhibitor class, which works by slowing the processes that cause lung scarring and loss of lung function. Because Nintedanib can cause significant side effects and requires regular monitoring, it should be taken only under the supervision of a healthcare professional.

Nintedanib is FDA-approved for the treatment of:

• Idiopathic pulmonary fibrosis (IPF)
• Chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype
• Interstitial lung disease associated with systemic sclerosis (SSc-ILD)

According to a pooled analysis of six clinical trials published on PubMed :

• Nintedanib was associated with a significantly longer estimated survival in people with IPF (idiopathic pulmonary fibrosis).
• Patients treated with Nintedanib had an average estimated survival of about 11.6 years, compared with about 3.7 years for patients who received a placebo.
• These results suggest that Nintedanib may help extend life expectancy in IPF by slowing disease progression.
• Results are observational and vary by patient.

Nintedanib is a tyrosine kinase inhibitor that works by blocking multiple pathways involved in lung tissue scarring (fibrosis). Specifically, it inhibits receptors for:

• Vascular endothelial growth factor (VEGFR)
• Fibroblast growth factor (FGFR)
• Platelet-derived growth factor (PDGFR)

In addition, Nintedanib also inhibits other kinases such as CSF1R, FLT‑3, and certain non‑receptor tyrosine kinases. This broader inhibitory activity extends to multiple signaling pathways that drive lung tissue scarring and fibrosis.

By targeting these receptors, Nintedanib helps to:

• Slow the progression of lung fibrosis
• Reduce the decline in lung function
• Potentially improve long-term outcomes in patients with idiopathic pulmonary fibrosis (IPF) or other progressive fibrosing interstitial lung diseases (ILDs)

Nintedanib does not cure IPF, but it helps control disease progression. It should be taken only under the supervision of a licensed provider, and regular monitoring is recommended to track side effects and effectiveness.

Liver Function Monitoring

• Nintedanib can cause elevated liver enzymes and drug‑induced liver injury.
• Liver function tests (ALT, AST, bilirubin) should be done before treatment, monthly for the first 3 months, and periodically thereafter.
• Use is not recommended in moderate to severe hepatic impairment.

Bleeding Risk

• Bleeding events (including serious bleeding) have been reported with Nintedanib.
• Use with caution in patients with known bleeding risk or those taking anticoagulants; the benefit should outweigh the risk.

Arterial Thromboembolic Events

• Arterial thromboembolic events, including myocardial infarction, have been reported.
• Use caution in patients at high cardiovascular risk (e.g., coronary artery disease).

Gastrointestinal Perforation

• Gastrointestinal perforation has been reported rarely.
• Use with caution in patients with recent abdominal surgery, diverticular disease, or risk factors for perforation; discontinue if perforation occurs.

Embryo‑Fetal Toxicity

• It might cause fetal harm when administered to a pregnant woman.
• Contraindicated in pregnancy; effective contraception is recommended during treatment and for at least 3 months after the last dose.

Gastrointestinal Disorders

• Diarrhea, vomiting, nausea, & abdominal pain are common adverse effects and may require supportive care, dose reduction, or treatment interruption.

Breastfeeding

• Nintedanib isn’t recommended during breastfeeding due to potential drug exposure and lack of safety data.

Who Cannot Take Nintedanib?

Nintedanib should not be taken by people with:

• Known hypersensitivity to Nintedanib or capsule ingredients.
• Severe hepatic impairment (Child‑Pugh C).
• Pregnant women (due to fetal harm risk).

Most of Nintedanib’s side effects are mild to moderate, but some can be serious and require medical attention. This is not a complete list of possible side effects, and effects may vary among individuals. Always inform your provider promptly if you experience any unusual or severe symptoms while taking Nintedanib.

Here are the key pharmacist‑recommended tips for taking Nintedanib capsules:

• Take Nintedanib exactly as prescribed by your provider. Do not change the dose or stop treatment without medical guidance.
• Do not crush, chew, or open the capsules unless instructed by your healthcare provider.
• Take Nintedanib capsules with food.
• Take at the same time each day to maintain consistent drug levels in your body.
• Swallow the medication whole with a full glass of water. Complete the full prescribed course, even if you feel well, to ensure optimal management of lung disease.
• If you miss a dose, take the next scheduled dose. Do not take two Nintedanib doses at the same time.
• Do not share Nintedanib capsules with others.

The recommended dose of Nintedanib depends on the specific chronic lung condition being treated. Dosing should always be determined by a provider based on the patient’s condition, liver function, and tolerability. The following table summarizes the FDA-approved dosing for Nintedanib (Ofev):

• The exact dose and duration should always be determined by a provider based on individual patient factors, including liver function, side effects, and overall health.

An overdose of Nintedanib may increase the risk of serious side effects. If a Nintedanib overdose is suspected, seek medical attention or contact your local poison control center. There is no specific antidote for its overdose, and treatment is generally supportive and symptom‑based.

Possible symptoms of Nintedanib overdose may include:

• Severe diarrhea, which may lead to dehydration
• Nausea or vomiting
• Abdominal or stomach pain
• Elevated liver enzymes or signs of liver injury (such as jaundice or dark urine)
• Dizziness or weakness

Severe overdose may increase the risk of liver toxicity, bleeding, or cardiovascular complications, especially in patients with existing medical conditions.

Both Nintedanib (Ofev) and Pirfenidone (Esbriet) are FDA‑approved antifibrotic therapies for idiopathic pulmonary fibrosis (IPF). Neither is universally “better”; the choice depends on patient tolerability, side‑effect profile, and comorbidities. Nintedanib is often preferred for patients with gastrointestinal sensitivity to pirfenidone, while Pirfenidone may be favored when liver enzyme monitoring is a concern.

Nintedanib (Ofev) alternatives are:

• Esbriet (pirfenidone)
• Pirespa (pirfenidone)

Nintedanib can interact with certain medications. This is not a complete list. Always tell your healthcare provider about all prescription, OTC, and herbal products you are taking. Some Nintedanib interactions are:

Nintedanib has 257+ known drug interactions, especially CYP3A4/P‑gp modulators; always consult a clinician before combining it with any medication.

When you buy Nintedanib capsules, it can be financially overwhelming as the cost of this medication can be high in the U.S., making it difficult for many patients to manage long-term therapy. At Polar Bear Meds, we help make Nintedanib more affordable by sourcing it from licensed Canadian pharmacies, offering savings of up to 80% compared to U.S. prices.

• Fast shipping: Orders typically arrive within 3–5 business days via Xpress Post.
• Additional savings for new customers: Use our coupon code WELCOMEPB10 for an extra 10% off.
• Safe and legal: All medications are authentic, regulated, and dispensed only with a valid prescription.

Buying Nintedanib online from Polar Bear Meds ensures you may access the treatment you need for your chronic lung condition safely, affordably, and conveniently.

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/205832Orig1s016lbl.pdf
• https://pubmed.ncbi.nlm.nih.gov/31179001/
• https://www.drugs.com/nintedanib.html
• https://www.webmd.com/drugs/ofev-nintedanib
• https://www.mayoclinic.org/drugs-supplements/nintedanib-oral-route/description/drg-20122674
• https://www.ncbi.nlm.nih.gov/books/NBK585049/